Editorial

Self-related Health and Blood Hypercoagulability: A Possible Mechanism for Cardiovascular Risk

Gordon D. O. Lowe¹

¹Academic Section of Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom

Thromb Haemost 2018;118:4–5.

Low self-related health (SRH) is one, single-item, measure of low chronic general health. SRH has been shown to be a predictor of total cardiovascular mortality in prospective studies of generally healthy populations.^{1–3} Several factors influence SRH scores, including medically diagnosed conditions, adverse lifestyle and other risk factors for total and cardiovascular mortality (including age), and individual resilience and resources to cope with declining health.^{4,5} Adjustment for major established risk factors does not, however, account for the association between SRH and total and cardiovascular mortality in population studies (–Fig. 1).^{6,7}

Furthermore, SRH scores were also predictive of recurrent coronary heart disease (CHD) events and death in patients with CHD at baseline.^{8,9}

Components of the haemostatic system play several roles in atherosclerosis, arterial thrombosis and cardiovascular disease.^{10–12} Several blood hypercoagulability measures, including plasma levels of fibrinogen, von Willebrand factor (VWF) antigen, fibrin D-dimer and tissue plasminogen activator antigen, are now established as risk factors for CHD, stroke and cardiovascular mortality in prospective studies.^{13–15} While plasma levels of these haemostatic factors are associated with several established cardiovascular risk factors (age, smoking, body mass index, blood pressure, cholesterol, triglycerides, and inflammatory markers), they are independently associated with cardiovascular risk after adjustment for these risk factors.^{13–15}

The association between SRH and components of the haemostatic system has not been previously studied. In this issue, Von Kanel and colleagues report the association of SRH with plasma levels of fibrinogen, VWF antigen, and fibrin D-dimer with SRH scores, in 190 patients within 48 hours of an acute coronary intervention for acute myocardial infarction.¹⁶ SRH, before their event, was rated on a visual analogue scale. In fully adjusted linear regression models, SRH was inversely associated with plasma fibrinogen ($r = -0.33$), VWF ($r = -0.19$) and D-dimer ($r = -0.25$). The Global Registry of Acute Coronary Events

(GRACE) risk score was similarly associated with these three haemostatic factors.

The authors suggest that haemostatic activation may potentially link SRH with cardiovascular outcome in patients with acute coronary syndromes, because previous studies of such patients have reported that plasma fibrinogen, VWF and D-dimer levels are associated with risk of major CVD events and death up to 2 years after discharge.^{17–20} They also note that these and other haemostatic factors may be expressed during inflammation in the central nervous system,²¹ raising the possibility that they may have effects on the neural contribution to SRH scores.

The authors acknowledge some limitations of their study. First, their subjects were a selected group of patients, who had satisfied the criteria for inclusion in a randomized controlled trial of the effects of early psychological counselling on the development of posttraumatic stress after acute myocardial infarction; most patients were men with higher education levels. They were asked to retrospectively score their SRH before their acute event, after their circulatory condition had stabilized. It is therefore possible that the acute effect influenced their recall of SRH.

Second, blood samples were also taken during the acute event, therefore measuring acute phase increments from basal levels in plasma levels of haemostatic factors (which were positively associated with GRACE risk scores), as well as the effects of antithrombotic treatments (although exploratory analyses adjusting for antithrombotic drug use did not significantly attenuate the associations of SRH with haemostatic factors).

Third, this cross-sectional study did not investigate the associations between SRH, plasma levels of haemostatic factors and long-term outcomes after acute coronary syndromes.

The study of Von Kanel and colleagues¹⁶ is of interest because it raises the hypothesis that activated haemostasis may be one potential causal mechanism for the established associations between low SRH and adverse cardiovascular outcomes. Further studies of this hypothesis should be prospective, and conducted in representative samples of both general populations and

Address for correspondence
Gordon D. O. Lowe, DSc, Institute
of Cardiovascular and Medical
Sciences, University of Glasgow,
Glasgow, Scotland G12 8TA,
United Kingdom
(e-mail: Gordon.
Lowe@glasgow.ac.uk).

Copyright © 2018 Schattauer

DOI <https://doi.org/10.1160/TH17-11-0836>.
ISSN 0340-6245.

Fig. 1 Low self-rated health, cardiovascular disease and mortality—interactive pathways.

persons with baseline cardiovascular disease. As fibrinogen, VWF, D-dimer and some other haemostatic factors are inflammatory reactants, inflammation markers such as C-reactive protein and interleukin-6 should also be studied. While haemostasis and antithrombotic drugs play important roles in cardiovascular disease and its prevention and treatment, there is increasing interest in inflammation and anti-inflammatory drugs in cardiovascular disease prevention.^{22–25}

References

- DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. *J Gen Intern Med* 2006;21(03):267–275
- Mavaddat N, Parker RA, Sanderson S, Mant J, Kinmonth AL. Relationship of self-rated health with fatal and non-fatal outcomes in cardiovascular disease: a systematic review and meta-analysis. *PLoS One* 2014;9(07):e103509
- Mavaddat N, van der Linde R, Parker R, et al. Relationship of self-related health to stroke incidence and mortality in older individuals with and without a history of stroke: a longitudinal study of the MRC Cognitive Function and Ageing (CFAS) population. *PLoS One* 2016;11(02):e0150178
- Jylhä M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. *Soc Sci Med* 2009;69(03):307–316
- Benyamini Y. Why does self-rated health predict mortality? An update on current knowledge and a research agenda for psychologists. *Psychol Health* 2011;26(11):1407–1413
- Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. *JAMA* 1998;279(08):585–592
- van der Linde RM, Mavaddat N, Luben R, et al. Self-rated health and cardiovascular disease incidence: results from a longitudinal population-based cohort in Norfolk, UK. *PLoS One* 2013;8(06):e65290
- Olson KL, Stiefel M, Ross C, et al. Self-related health among patients with coronary artery disease enrolled in a cardiovascular reduction service. *Popul Health Manag* 2016;19(01):24–30
- Thombs BD, Ziegelstein RC, Stewart DE, Abbey SE, Parakh K, Grace SL. Usefulness of a single-item general self-rated health question to predict mortality 12 months after an acute coronary syndrome. *Eur J Cardiovasc Prev Rehabil* 2008;15(04):479–481
- Borisoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. *N Engl J Med* 2011;364(18):1746–1760
- ten Cate H, Lowe G. Coagulation proteases and cardiovascular disease. *Thromb Haemost* 2014;112(05):858–859
- Spronk H, Padro T, Siland J, et al. Atherothrombosis and cardiovascular disease; position paper from the 2nd Maastricht Consensus Conference on Thrombosis. *Thromb Haemost* 2018; In press
- Danesh J, Lewington S, Thompson SG, et al; Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *JAMA* 2005;294(14):1799–1809
- Lowe G, Rumley A. The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us? *Thromb Haemost* 2014; 112(05):860–867
- Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. *PLoS One* 2013;8(02):e55175
- Von Kanel R, Meister-Landgraf R, Schmid J-P, et al. Low self-rated health is related to blood hypercoagulability in patients admitted with acute myocardial infarction. *Thromb Haemost* 2018; In press
- Toss H, Lindahl B, Siegbahn A, Wallentin L; FRISC Study Group. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. *Fragsin during Instability in Coronary Artery Disease. Circulation* 1997;96(12):4204–4210
- Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Coagulation activity and clinical outcome in unstable coronary artery disease. *Arterioscler Thromb Vasc Biol* 2001;21(06):1059–1064
- Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. *Blood* 2005;105(02):526–532
- Brügger-Andersen T, Pönitz V, Staines H, Grundt H, Hetland Ø, Nilsen DW. The prognostic utility of D-dimer and fibrin monomer at long-term follow-up after hospitalization with coronary chest pain. *Blood Coagul Fibrinolysis* 2008;19(07):701–707
- Chapman J. Coagulation in inflammatory diseases of the central nervous system. *Semin Thromb Hemost* 2013;39(08):876–880
- Kaptoge S, Di Angelantonio E, Pennells L, et al; Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med* 2012;367(14):1310–1320
- Sarwar N, Butterworth AS, Freitag DF, et al; IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* 2012;379(9822):1205–1213
- Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. *Eur Heart J* 2014;35(09):578–589
- Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377(12):1119–1131